CJC-1295 + Ipamorelin — the GHRH/GHRP research pairing

CJC-1295 and Ipamorelin are two different peptides with two different receptor targets that together model the natural pulsatile rhythm of growth-hormone-releasing-hormone signalling. The pairing is the most-studied paired-peptide stack in the somatotropic-research category, and the reason has more to do with receptor pharmacology than with anything you will read in marketing copy.

What the pairing actually is

The somatotropic axis produces growth hormone in pulses, regulated by two parallel signals from the hypothalamus: growth-hormone-releasing hormone (GHRH), which raises the pituitary’s baseline readiness to release GH, and ghrelin, which produces acute GH release on demand via the GHS-R1a receptor. Sleep-period GH pulses, exercise-induced GH peaks, and meal-related GH dynamics all run through some combination of these two upstream signals.

CJC-1295 is the long-acting GHRH side of that pharmacology. It is a 30-residue analogue of the active fragment of native GHRH (residues 1-29 of the parent protein) with four amino-acid substitutions for protease resistance and a maleimidopropionamide-lysine modification at the C-terminus that covalently binds plasma albumin [1]. The albumin binding is what extends the half-life from ~30 minutes (native GHRH) to ~8 days. Note that the standalone “CJC-1295 no-DAC” sold by research-supply vendors omits the maleimidopropionamide group and reverts to a ~30-minute half-life, while the “CJC-1295 DAC” form keeps it.

Ipamorelin is the acute-pulse side. It is a 5-residue synthetic pentapeptide (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2) and a selective agonist of the GHS-R1a receptor — the ghrelin receptor on pituitary somatotroph cells. The 1998 foundational paper established that Ipamorelin produces GH release comparable to GHRP-6 but without the cortisol, prolactin, or aldosterone elevations that limit older GHRPs in research [2]. The receptor selectivity is what makes Ipamorelin the cleaner research tool of the GHRP class.

Why the pairing — receptor logic, not marketing

Co-administering a GHRH analogue and a GHS-R1a agonist activates two parallel intracellular signalling pathways in the same pituitary somatotroph cells. GHRH receptor activation runs through G(s)-coupled cAMP elevation; GHS-R1a activation runs primarily through G(q)-coupled phospholipase C → intracellular calcium release. The two pathways converge on synaptic-vesicle GH release with a synergistic, not just additive, effect — the GH release observed from co-administration in animal models is larger than the sum of the individual compounds tested separately.

• CJC-1295 (DAC form) raises baseline GHRH tone. Continuous albumin-bound circulation produces a sustained elevation in baseline GH-pulse amplitude. In GHRH-knockout mice, once-daily CJC-1295 normalises growth-velocity endpoints [3].
• Ipamorelin produces the pulse. Acute administration triggers a 30-90 minute GH peak via the GHS-R1a pathway. Without an elevated baseline, the peak is smaller; with CJC-1295 raising baseline, the peak is amplified.
• Adjacent receptor work — GHS-R1a heterogeneity, alternative ghrelin-pathway agonists — has built up around the foundational receptor pharmacology and is summarised in recent imaging-agent and receptor-pharmacology reviews.

Honest take: the pairing is one of the cleaner receptor-pharmacology stories in the research-peptide category. Each compound has a defined target, the two targets are complementary, and the synergy is real in animal models — but the field has not advanced to large human RCTs that establish endpoints beyond GH pulsatility itself.

What the human data shows

Human data on CJC-1295 is limited to early phase-1 pharmacokinetic and GH-pulsatility studies in healthy volunteers, conducted by ConjuChem (the original sponsor) before the program was discontinued. The published material consistently shows that single doses of CJC-1295 produce a 2-10× elevation in 24-hour mean GH and IGF-1 levels, sustained for up to 7-10 days. The discontinuation of formal development means there are no published phase-2 efficacy trials with clinical endpoints.

Ipamorelin moved further through clinical development than CJC-1295. Helsinn Therapeutics ran a phase-2 program targeting post-operative ileus and reached interim readouts before discontinuing the program. The safety profile in those trials was clean at the doses tested (sub-mg subcutaneous range); efficacy on the surgical-ileus endpoint did not reach the bar Helsinn required to advance.

Co-administration human data is essentially anecdotal — there are no published controlled trials of the CJC-1295 + Ipamorelin pairing in humans. The pairing logic above is derived from animal pharmacology and from cell-based receptor work.

The UAE research-supply landscape

Both compounds are supplied in the UAE as lyophilised powder. CJC-1295 most commonly ships as the no-DAC form (5 mg vial); the DAC form is harder to find but is the version most-cited in the published pharmacology work. Ipamorelin most commonly ships as a 5 mg or 2 mg per vial. Pairing-format vials (single vial containing both compounds at known stoichiometry) are the most-practical research format and reduce the need to handle two separate lyophilised powders. Researchers can review the protocol options on the Ipamorelin 5 mg consultation or the paired-stack consultation page.

Open questions

Open research questions:

• Long-term tachyphylaxis. Chronic GHRH-receptor stimulation has theoretical desensitisation risk; published animal data has run weeks not months, leaving the chronic-administration window uncharacterised.
• IGF-1 setpoint changes. The sustained elevation in GH from CJC-1295 (DAC) is mirrored by elevated IGF-1; whether the IGF-1 setpoint returns to baseline after washout is not well-characterised in the published literature.
• Why both compounds were discontinued. The phase-2 termination for Ipamorelin (post-operative ileus) and the discontinuation of the CJC-1295 program by ConjuChem are not extensively documented in the peer-reviewed record. Whether this reflects efficacy issues, safety signals, or business decisions is hard to determine from public material.
• Pairing dose-response. The optimal CJC-1295 : Ipamorelin ratio for synergistic effect has not been published; the commercial blends use approximately 1:1 by mass but this is by convention rather than from a published dose-response curve.

Further reading

Peer-reviewed citations used inline:

• [1] Jetté et al. — Endocrinology 2005. Foundational paper identifying CJC-1295 as a long-lasting GHRH analog via albumin bioconjugation.
• [2] Raun et al. — Eur J Endocrinol 1998. Ipamorelin, the first selective growth hormone secretagogue.
• [3] Alba et al. — Endocrinology 2006. Once-daily CJC-1295 normalises growth in the GHRH-knockout mouse.
• [4] Yin, Lin et al. — Endocrinology 2012. The growth hormone secretagogue receptor (GHS-R) — pharmacology + signalling pathways.

Last reviewed 26 May 2026. Wellness Labs supplies Ipamorelin 5 mg and CJC-1295 (no-DAC) + Ipamorelin 5 mg paired blends as research-grade lyophilised powder. Editorial inbox: info@uaewellnesslab.com.